PDF herunterladen
Semin Liver Dis 2019; 39(02): 249-260
DOI: 10.1055/s-0039-1678728
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Current Knowledge of Occult Hepatitis B Infection and Clinical Implications

Terry Cheuk-Fung Yip
1   Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China
2   Department of Medicine and Therapeutics, The Chinese University of Hong Kong; Hong Kong SAR, People's Republic of China
,
Grace Lai-Hung Wong
1   Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China
2   Department of Medicine and Therapeutics, The Chinese University of Hong Kong; Hong Kong SAR, People's Republic of China
3   State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong; Hong Kong SAR, People's Republic of China
› Institutsangaben Financial SupportThis work was partly supported by the Direct Grant of The Chinese University of Hong Kong (Reference no: 4054345).
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. März 2019 (online)

    Lizenzen und Reprints

Abstract

Occult hepatitis B infection (OBI) is a status of undetectable serum hepatitis B surface antigen (HBsAg) yet detectable serum and/or intrahepatic hepatitis B virus (HBV) DNA. Mutations in the preS1, preS2, and S regions of the HBsAg gene may result in undetectable HBsAg. OBI may either result from a self-limiting acute hepatitis, or in patients with chronic hepatitis B who achieved HBsAg seroclearance, which refers to the loss of detectability of serum HBsAg with or without antibody to HBsAg (anti-HBs) in chronic hepatitis B (CHB) patients. HBsAg seroclearance contributes to a significant proportion of population in seropositive OBI. Both spontaneous and antiviral treatment-induced HBsAg seroclearance rarely happens; yet both types of HBsAg seroclearance are durable. CHB patients who achieve HBsAg seroclearance generally have a favorable clinical course. There is still a low yet definite risk of HCC occurrence, particularly in male CHB patients who achieve HBsAg seroclearance after being 50 years old. Clinical implications of OBI include occurrence of cirrhosis and HCC, liver transplantation, blood products transfusion, hemodialysis, and so on. A potentially life-threatening condition would be OBI reactivation in patients during immunosuppression therapy, especially in the setting of intensified immunosuppression including in onco-hematological patients (those receiving hematopoietic stem cell transplantation and treated with the anti-CD20 monoclonal antibody [e.g., rituximab]). With more new insights into these two conditions, CHB patients who achieved HBsAg seroclearance generally have benign clinical course and good prognosis. Sensitive assay for serum HBV DNA should be considered to establish the presence of OBI in the clinical settings mentioned earlier, which will affect the management plan.

Keywords

antiviral therapy - cirrhosis - hepatocellular carcinoma - liver-related mortality

Authorship Statement

Terry Yip and Grace Wong were responsible for the interpretation of data, the drafting, and critical revision of the manuscript for important intellectual content.


Financial Support

This work was partly supported by the Direct Grant of The Chinese University of Hong Kong (Reference no: 4054345).


 

  • Reference

  • 1 World Health Organization. Hepatitis B Fact Sheet N204: Hepatitis B. http://www.who.int/mediacentre/factsheets/fs2204/en/ . Accessed April 30, 2018
    PubMed
  • 2 Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62 (04) 956-967
    CrossrefPubMedGoogle Scholar
  • 3 Wong GL, Chan HL, Mak CW. , et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58 (05) 1537-1547
    CrossrefPubMedGoogle Scholar
  • 4 Liu K, Choi J, Wong VW. , et al. Tenofovir treatment reduces hepatocellular carcinoma and deaths in chronic hepatitis B patients with liver cirrhosis [abstract]. Hepatol Int 2017; 11 (Suppl. 01) S84
    PubMedGoogle Scholar
  • 5 Sarin SK, Kumar M, Lau GK. , et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10 (01) 1-98
    PubMedGoogle Scholar
  • 6 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67 (02) 370-398
    CrossrefPubMedGoogle Scholar
  • 7 Terrault NA, Lok ASF, McMahon BJ. , et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67 (04) 1560-1599
    CrossrefPubMedGoogle Scholar
  • 8 Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9 (04) 243-257
    CrossrefPubMedGoogle Scholar
  • 9 Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46 (01) 160-170
    CrossrefPubMedGoogle Scholar
  • 10 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012; 25 (01) 142-163
    CrossrefPubMedGoogle Scholar
  • 11 Kim H, Lee SA, Won YS, Lee H, Kim BJ. Occult infection related hepatitis B surface antigen variants showing lowered secretion capacity. World J Gastroenterol 2015; 21 (06) 1794-1803
    CrossrefPubMedGoogle Scholar
  • 12 Raimondo G, Allain JP, Brunetto MR. , et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49 (04) 652-657
    CrossrefPubMedGoogle Scholar
  • 13 Wu T, Kwok RM, Tran TT. Isolated anti-HBc: the relevance of hepatitis B core antibody -- a review of new issues. Am J Gastroenterol 2017; 112 (12) 1780-1788
    CrossrefPubMedGoogle Scholar
  • 14 Gerlich WH, Bremer C, Saniewski M. , et al. Occult hepatitis B virus infection: detection and significance. Dig Dis 2010; 28 (01) 116-125
    CrossrefPubMedGoogle Scholar
  • 15 Chan HL, Tsang SW, Leung NW. , et al. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol 2002; 97 (05) 1211-1215
    CrossrefPubMedGoogle Scholar
  • 16 Hou J, Wang Z, Cheng J. , et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 2001; 34 (05) 1027-1034
    CrossrefPubMedGoogle Scholar
  • 17 Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol 2013; 59 (04) 696-700
    CrossrefPubMedGoogle Scholar
  • 18 Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004; 39 (01) 51-57
    CrossrefPubMedGoogle Scholar
  • 19 Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol 2016; 22 (39) 8720-8734
    CrossrefPubMedGoogle Scholar
  • 20 Kishk R, Nemr N, Elkady A. , et al. Hepatitis B surface gene variants isolated from blood donors with overt and occult HBV infection in north eastern Egypt. Virol J 2015; 12: 153
    CrossrefPubMedGoogle Scholar
  • 21 Sofian M, Aghakhani A, Izadi N. , et al. Lack of occult hepatitis B virus infection among blood donors with isolated hepatitis B core antibody living in an HBV low prevalence region of Iran. Int J Infect Dis 2010; 14 (04) e308-e310
    PubMedGoogle Scholar
  • 22 Minuk GY, Sun DF, Greenberg R. , et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004; 40 (05) 1072-1077
    CrossrefPubMedGoogle Scholar
  • 23 Zhu HL, Li X, Li J, Zhang ZH. Genetic variation of occult hepatitis B virus infection. World J Gastroenterol 2016; 22 (13) 3531-3546
    CrossrefPubMedGoogle Scholar
  • 24 Morales-Romero J, Vargas G, García-Román R. Occult HBV infection: a faceless enemy in liver cancer development. Viruses 2014; 6 (04) 1590-1611
    CrossrefPubMedGoogle Scholar
  • 25 Yuen MF, Lee CK, Wong DK. , et al. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut 2010; 59 (10) 1389-1393
    CrossrefPubMedGoogle Scholar
  • 26 Carman WF, Zanetti AR, Karayiannis P. , et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336 (8711): 325-329
    CrossrefPubMedGoogle Scholar
  • 27 Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345 (8962): 1406-1407
    CrossrefPubMedGoogle Scholar
  • 28 Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 2004; 127 (05) 1356-1371
    CrossrefPubMedGoogle Scholar
  • 29 Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Günther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology 2005; 42 (01) 93-103
    CrossrefPubMedGoogle Scholar
  • 30 Wang Y, Zhu P, Qiu J. , et al. Identification and characterization of interferon signaling-related microRNAs in occult hepatitis B virus infection. Clin Epigenetics 2017; 9: 101
    CrossrefPubMedGoogle Scholar
  • 31 Chen Y, Li L, Zhou Z, Wang N, Zhang CY, Zen K. A pilot study of serum microRNA signatures as a novel biomarker for occult hepatitis B virus infection. Med Microbiol Immunol (Berl) 2012; 201 (03) 389-395
    CrossrefPubMedGoogle Scholar
  • 32 Bläckberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000; 33 (06) 992-997
    CrossrefPubMedGoogle Scholar
  • 33 Cabrerizo M, Bartolomé J, Caramelo C, Barril G, Carreno V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000; 32 (01) 116-123
    CrossrefPubMedGoogle Scholar
  • 34 Mu SC, Lin YM, Jow GM, Chen BF. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol 2009; 50 (02) 264-272
    CrossrefPubMedGoogle Scholar
  • 35 Wong GL, Chan HL, Chan HY. , et al. Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. Aliment Pharmacol Ther 2016; 43 (01) 145-153
    CrossrefPubMedGoogle Scholar
  • 36 Arababadi MK, Nasiri Ahmadabadi B, Kennedy D. Current information on the immunologic status of occult hepatitis B infection. Transfusion 2012; 52 (08) 1819-1826
    CrossrefPubMedGoogle Scholar
  • 37 Vivekanandan P, Thomas D, Torbenson M. Hepatitis B viral DNA is methylated in liver tissues. J Viral Hepat 2008; 15 (02) 103-107
    PubMedGoogle Scholar
  • 38 Pollicino T, Belloni L, Raffa G. , et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130 (03) 823-837
    CrossrefPubMedGoogle Scholar
  • 39 Vivekanandan P, Kannangai R, Ray SC, Thomas DL, Torbenson M. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 2008; 46 (08) 1227-1236
    CrossrefPubMedGoogle Scholar
  • 40 Grewal J, Dellinger CA, Yung WK. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 2007; 356 (15) 1591-1592
    CrossrefPubMedGoogle Scholar
  • 41 Tan A, Koh S, Bertoletti A. Immune response in hepatitis B virus infection. Cold Spring Harb Perspect Med 2015; 5 (08) a021428
    CrossrefPubMedGoogle Scholar
  • 42 de Niet A, Stelma F, Jansen L. , et al. Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy. J Hepatol 2016; 64 (03) 539-546
    CrossrefPubMedGoogle Scholar
  • 43 Yuen MF, Wong DK, Fung J. , et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135 (04) 1192-1199
    CrossrefPubMedGoogle Scholar
  • 44 Loriot MA, Marcellin P, Walker F. , et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol 1997; 27 (02) 251-258
    CrossrefPubMedGoogle Scholar
  • 45 Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15 (02) 133-143
    CrossrefPubMedGoogle Scholar
  • 46 Chan HL, Wong VW, Tse AM. , et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5 (12) 1462-1468
    CrossrefPubMedGoogle Scholar
  • 47 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology 2017; 66 (04) 1296-1313
    CrossrefPubMedGoogle Scholar
  • 48 Kim GA, Lim YS, An J. , et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014; 63 (08) 1325-1332
    CrossrefPubMedGoogle Scholar
  • 49 Yip TC, Wong GL, Wong VW. , et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol 2017; 68: 63-72
    PubMedGoogle Scholar
  • 50 Yip TC, Wong VW, Tse YK. , et al. Hepatitis B surface antigen seroclearance in a cohort of 154,740 patients with chronic hepatitis B: a 15-year follow-up study. Hepatol Int 2017; 11: S75
    PubMedGoogle Scholar
  • 51 Buster EH, Flink HJ, Cakaloglu Y. , et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135 (02) 459-467
    CrossrefPubMedGoogle Scholar
  • 52 Lauret E, González-Diéguez ML, Rodríguez M. , et al. Long-term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance. Liver Int 2015; 35 (01) 140-147
    CrossrefPubMedGoogle Scholar
  • 53 Seto WK, Tanaka Y, Wong DK. , et al. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. Liver Int 2016; 36 (05) 642-650
    CrossrefPubMedGoogle Scholar
  • 54 Ozeki I, Nakajima T, Suii H. , et al. Analysis of hepatitis B surface antigen (HBsAg) using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays. Hepatol Res 2018; 48 (03) E263-E274
    CrossrefPubMedGoogle Scholar
  • 55 Seto WK, Cheung KS, Wong DK. , et al. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. J Gastroenterol 2016; 51 (05) 487-495
    CrossrefPubMedGoogle Scholar
  • 56 Chi H, Wong D, Peng J. , et al. Durability of response after hepatitis B surface antigen seroclearance during nucleos(t)ide analogue treatment in a multiethnic cohort of chronic hepatitis B patients: results after treatment cessation. Clin Infect Dis 2017; 65 (04) 680-683
    CrossrefPubMedGoogle Scholar
  • 57 Yip TC, Chan HL, Wong VW, Tse YK, Lam KL, Wong GL. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol 2017; 67 (05) 902-908
    CrossrefPubMedGoogle Scholar
  • 58 Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123 (04) 1084-1089
    CrossrefPubMedGoogle Scholar
  • 59 Ahn SH, Park YN, Park JY. , et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42 (02) 188-194
    PubMedGoogle Scholar
  • 60 Simonetti J, Bulkow L, McMahon BJ. , et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51 (05) 1531-1537
    CrossrefPubMedGoogle Scholar
  • 61 Cheuk-Fung Yip T, Wai-Sun Wong V, Lik-Yuen Chan H. , et al. Effects of diabetes and glycemic control on risk of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 2018; 16 (05) 765-773.e2
    CrossrefPubMedGoogle Scholar
  • 62 Bruix J, Sherman M. ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022
    CrossrefPubMedGoogle Scholar
  • 63 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383 (9930): 1749-1761
    CrossrefPubMedGoogle Scholar
  • 64 Martin CM, Welge JA, Shire NJ, Shata MT, Sherman KE, Blackard JT. Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. Cytokine 2009; 47 (03) 194-198
    CrossrefPubMedGoogle Scholar
  • 65 Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 2016; 64 (1, Suppl) S84-S101
    CrossrefPubMedGoogle Scholar
  • 66 Saitta C, Tripodi G, Barbera A. , et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 2015; 35 (10) 2311-2317
    CrossrefPubMedGoogle Scholar
  • 67 Pollicino T, Squadrito G, Cerenzia G. , et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126 (01) 102-110
    CrossrefPubMedGoogle Scholar
  • 68 Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011; 32 (08) 1122-1132
    CrossrefPubMedGoogle Scholar
  • 69 Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles. J Virol 2018 (epub ahead of print) Doi: 10.1128/JVI.02007-17
    PubMedGoogle Scholar
  • 70 Shimizu Y. T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World J Gastroenterol 2012; 18 (20) 2443-2451
    CrossrefPubMedGoogle Scholar
  • 71 Kim MJ, Kwon OS, Chung NS. , et al. [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis]. Korean J Hepatol 2008; 14 (01) 67-76
    CrossrefPubMedGoogle Scholar
  • 72 Nishikawa H, Osaki Y. Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer 2013; 4 (06) 473-480
    CrossrefPubMedGoogle Scholar
  • 73 Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection?. Lancet 2005; 365 (9460): 638-640
    CrossrefPubMedGoogle Scholar
  • 74 Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 2012; 32 (02) 231-240
    CrossrefPubMedGoogle Scholar
  • 75 Marcellin P, Pequignot F, Delarocque-Astagneau E. , et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48 (02) 200-207
    CrossrefPubMedGoogle Scholar
  • 76 Xie M, Rao W, Yang T. , et al. Occult hepatitis B virus infection predicts de novo hepatitis B infection in patients with alcoholic cirrhosis after liver transplantation. Liver Int 2015; 35 (03) 897-904
    CrossrefPubMedGoogle Scholar
  • 77 Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52 (02) 272-279
    CrossrefPubMedGoogle Scholar
  • 78 Dickson RC, Everhart JE, Lake JR. , et al; The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113 (05) 1668-1674
    CrossrefPubMedGoogle Scholar
  • 79 Franz C, Perez RdeM, Zalis MG. , et al. Prevalence of occult hepatitis B virus infection in kidney transplant recipients. Mem Inst Oswaldo Cruz 2013; 108 (05) 657-660
    CrossrefPubMedGoogle Scholar
  • 80 Bae E, Park CH, Ki CS. , et al. Prevalence and clinical significance of occult hepatitis B virus infection among renal transplant recipients in Korea. Scand J Infect Dis 2012; 44 (10) 788-792
    CrossrefPubMedGoogle Scholar
  • 81 Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 2017; 152 (06) 1297-1309
    CrossrefPubMedGoogle Scholar
  • 82 Lo CM, Fan ST, Liu CL. , et al. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl 2003; 9 (08) 827-832
    CrossrefPubMedGoogle Scholar
  • 83 Caviglia GP, Abate ML, Tandoi F. , et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection. J Hepatol 2018; 69 (02) 301-307 Doi: 10.1016/j.jhep.2018.03.021
    CrossrefPubMedGoogle Scholar
  • 84 Chang JJ, Mohtashemi N, Bhattacharya D. Significance and management of isolated hepatitis B core antibody (anti-HBc) in HIV and HCV: strategies in the DAA era. Curr HIV/AIDS Rep 2018; 15 (02) 172-181
    CrossrefPubMedGoogle Scholar
  • 85 Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR. ; HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011; 54 (02) 434-442
    CrossrefPubMedGoogle Scholar
  • 86 Rodríguez-Iñigo E, Bartolomé J, Ortiz-Movilla N. , et al. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J Virol 2005; 79 (24) 15578-15581
    CrossrefPubMedGoogle Scholar
  • 87 Chen SY, Kao CF, Chen CM. , et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003; 278 (01) 591-607
    CrossrefPubMedGoogle Scholar
  • 88 Miura Y, Shibuya A, Adachi S. , et al. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res 2008; 38 (06) 546-556
    CrossrefPubMedGoogle Scholar
  • 89 Chen HY, Su TH, Tseng TC. , et al. Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: a 10-year follow-up. J Formos Med Assoc 2017; 116 (09) 697-704
    CrossrefPubMedGoogle Scholar
  • 90 Bellecave P, Gouttenoire J, Gajer M. , et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009; 50 (01) 46-55
    CrossrefPubMedGoogle Scholar
  • 91 Eyre NS, Phillips RJ, Bowden S. , et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol 2009; 51 (03) 446-457
    CrossrefPubMedGoogle Scholar
  • 92 Yang D, Zuo C, Wang X. , et al. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci U S A 2014; 111 (13) E1264-E1273
    CrossrefPubMedGoogle Scholar
  • 93 Liu CJ, Chuang WL, Sheen IS. , et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology 2018; 154 (04) 989-997
    CrossrefPubMedGoogle Scholar
  • 94 Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35 (01) 14-20
    CrossrefPubMedGoogle Scholar
  • 95 Wang T, Shen C, Chen L, Liu S, Ji Y. Association of human leukocyte antigen polymorphisms with occult hepatitis B virus infection in a Shaanxi Han population. J Gene Med 2017 19. (9-10). doi: 10.1002/jgm.2987
    PubMedGoogle Scholar
  • 96 Filippini P, Coppola N, Pisapia R. , et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20 (09) 1253-1260
    CrossrefPubMedGoogle Scholar
  • 97 Palmore TN, Shah NL, Loomba R. , et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009; 7 (10) 1130-1137
    CrossrefPubMedGoogle Scholar
  • 98 Kubo S, Tamori A, Ohba K. , et al. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis. Dig Dis Sci 2001; 46 (11) 2408-2414
    CrossrefPubMedGoogle Scholar
  • 99 Hsu C, Tsou HH, Lin SJ. , et al; Taiwan Cooperative Oncology Group. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014; 59 (06) 2092-2100
    CrossrefPubMedGoogle Scholar
  • 100 Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113 (14) 3147-3153
    CrossrefPubMedGoogle Scholar
  • 101 Seto WK, Chan TS, Hwang YY. , et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014; 32 (33) 3736-3743
    CrossrefPubMedGoogle Scholar
  • 102 Phipps C, Chen Y, Tan D. Lymphoproliferative disease and hepatitis B reactivation: challenges in the era of rapidly evolving targeted therapy. Clin Lymphoma Myeloma Leuk 2016; 16 (01) 5-11
    CrossrefPubMedGoogle Scholar
  • 103 Muraishi J, Shibata M, Honma Y, Hiura M, Abe S, Harada M. Reactivation of occult hepatitis B virus infection 27 months after the end of chemotherapy including rituximab for malignant lymphoma. Intern Med 2017; 56 (15) 1967-1971
    CrossrefPubMedGoogle Scholar
  • 104 Francisci D, Falcinelli F, Schiaroli E. , et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010; 38 (01) 58-61
    CrossrefPubMedGoogle Scholar
  • 105 Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009; 51 (04) 798-809
    CrossrefPubMedGoogle Scholar
  • 106 Tang X, Allain JP, Wang H. , et al. Incidence of hepatitis B virus infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide. J Viral Hepat 2018; 25 (09) 1008-1016
    CrossrefPubMedGoogle Scholar
  • 107 Safic Stanic H, Babic I, Maslovic M. , et al. Three-Year Experience in NAT screening of blood donors for transfusion transmitted viruses in Croatia. Transfus Med Hemother 2017; 44 (06) 415-420
    CrossrefPubMedGoogle Scholar
  • 108 Ghosh K, Mishra KK, Trivedi A, Sosa S, Patel K. Assessment of semi-automated nucleic acid testing programme in a regional blood transfusion centre. Br J Biomed Sci 2017; 74 (01) 42-47
    PubMedGoogle Scholar
  • 109 Seo DH, Whang DH, Song EY, Kim HS, Park Q. Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. Transfusion 2011; 51 (08) 1840-1846
    CrossrefPubMedGoogle Scholar
  • 110 Stolz M, Tinguely C, Graziani M. , et al. Efficacy of individual nucleic acid amplification testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low-endemic region. Transfusion 2010; 50 (12) 2695-2706
    CrossrefPubMedGoogle Scholar
  • 111 González R, Torres P, Castro E. , et al. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. Transfusion 2010; 50 (01) 221-230
    CrossrefPubMedGoogle Scholar
  • 112 Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat 2010; 17 (01) 1-15
    PubMedGoogle Scholar
  • 113 Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006; 36 (Suppl. 01) S33-S44
    PubMedGoogle Scholar
  • 114 Satake M, Taira R, Yugi H. , et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007; 47 (07) 1197-1205
    CrossrefPubMedGoogle Scholar
  • 115 O'Brien SF, Fearon MA, Yi QL. , et al. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion 2007; 47 (10) 1809-1815
    CrossrefPubMedGoogle Scholar
  • 116 Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008; 48 (06) 1022-1025
    CrossrefPubMedGoogle Scholar
  • 117 Su TH, Chen PJ, Chen TC. , et al. The clinical significance of occult hepatitis B transfusion in Taiwan--a look-back study. Transfus Med 2011; 21 (01) 33-41
    CrossrefPubMedGoogle Scholar
  • 118 Yuen MF, Wong DK, Lee CK. , et al. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin Infect Dis 2011; 52 (05) 624-632
    CrossrefPubMedGoogle Scholar
  • 119 Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Rev Vaccines 2014; 13 (11) 1317-1326
    CrossrefPubMedGoogle Scholar
  • 120 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148 (01) 221-244.e3
    CrossrefPubMedGoogle Scholar